NYSE: JBS
JBS N.V.CIK 0001791942 · SIC 2011 · Meat Packing Plants
No XBRL size data yet — common for recent IPOs and new registrants (SEC companyfacts lag), foreign filers reporting in non-USD, or non-standard filers.
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (VC 10-Q) is open in full — no account needed.
424B3
Filed Oct 22, 2026
Summary not yet generated.
8-K
Filed Sep 15, 2026
· Period ending Sep 15, 2026
Summary not yet generated.
Partner
Trade JBS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Aug 19, 2026
· Period ending Aug 18, 2026
Summary not yet generated.
8-K
Filed Aug 11, 2026
· Period ending Aug 10, 2026
Summary not yet generated.
10-Q
Filed Aug 10, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
424B3
Filed Dec 11, 2025
Summary not yet generated.
424B3
Filed May 16, 2025
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 10, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Statements of income (Unaudited)
(in thousands)
| Description | Six-month period ended June 30, 2026 | Six-month period ended June 30, 2025 |
|---|---|---|
| NET REVENUE | 45,508,205 | 40,524,176 |
| Cost of sales | (40,595,716) | (35,067,104) |
| GROSS PROFIT | 4,912,489 | 5,457,072 |
| Selling expenses | (2,713,527) | (2,394,637) |
| General and administrative expenses | (1,143,749) | (1,078,711) |
| Other income | 69,811 | 48,070 |
| Other expenses | (43,428) | (43,799) |
| NET OPERATING EXPENSES | (3,830,893) | (3,469,077) |
| OPERATING PROFIT | 1,081,596 | 1,987,995 |
| Finance income | 307,828 | 305,097 |
| Finance expense | (1,317,609) | (873,047) |
| NET FINANCE EXPENSE | (1,009,781) | (567,950) |
| Share of profit of equity-accounted investees, net of tax | 14,794 | 10,556 |
| PROFIT BEFORE TAXES | 86,609 | 1,430,601 |
| Current income taxes | (51,871) | (390,457) |
| Deferred income taxes | 110,677 | 110,504 |
| TOTAL INCOME TAXES | 58,806 | (279,953) |
| NET INCOME | 145,415 | 1,150,648 |
| ATTRIBUTABLE TO: | ||
| Company shareholders | 118,485 | 1,028,303 |
| Non-controlling interest | 26,930 | 122,345 |
| 145,415 | 1,150,648 | |
| Basic earnings per share common shares (US$) | 0.11 | 0.93 |
| Diluted earnings per share common shares (US$) | 0.11 | 0.93 |
Statements of financial position
(in thousands)
| Description | (Unaudited) June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | 3,469,120 | 4,565,136 |
| Margin cash | 168,301 | 159,562 |
| Trade accounts receivable | 3,555,443 | 4,231,924 |
| Dividends receivable | — | 1,465 |
| Inventories | 6,996,200 | 6,107,165 |
| Biological assets | 1,810,275 | 1,826,766 |
| Recoverable taxes | 1,088,854 | 957,211 |
| Derivative assets | 118,170 | 155,602 |
| Other current assets | 550,408 | 433,372 |
| TOTAL CURRENT ASSETS | 17,756,771 | 18,438,203 |
| NON-CURRENT ASSETS | ||
| Long-term investments | 50,949 | 45,780 |
| Recoverable taxes | 2,085,715 | 1,874,572 |
| Biological assets | 660,066 | 611,799 |
| Related party receivables | 32,709 | 41,231 |
| Deferred income taxes | 656,067 | 547,014 |
| Other non-current assets | 563,888 | 488,803 |
| Investments in equity-accounted investees | 225,663 | 171,612 |
| Property, plant and equipment | 14,415,997 | 13,645,658 |
| Right of use assets | 1,621,847 | 1,613,647 |
| Intangible assets | 1,784,787 | 1,825,592 |
| Goodwill | 5,983,917 | 5,852,575 |
| TOTAL NON-CURRENT ASSETS | 28,081,605 | 26,718,283 |
| TOTAL ASSETS | 45,838,376 | 45,156,486 |
| LIABILITIES AND EQUITY | ||
| CURRENT LIABILITIES | ||
| Trade accounts payable | 5,851,662 | 6,198,100 |
| Supply chain finance | 1,195,548 | 1,134,459 |
| Loans and financing | 1,334,897 | 833,085 |
| Income taxes | 122,923 | 288,030 |
| Other taxes payable | 187,613 | 152,959 |
| Payroll and social charges | 1,378,331 | 1,560,159 |
| Lease liabilities | 368,699 | 354,887 |
| Dividends payable | 117 | — |
| Provisions for legal proceedings | 220,431 | 159,217 |
| Derivative liabilities | 116,808 | 156,405 |
| Other current liabilities | 805,586 | 704,509 |
| TOTAL CURRENT LIABILITIES | 11,582,615 | 11,541,810 |
| NON-CURRENT LIABILITIES | ||
| Loans and financing | 21,315,792 | 20,257,483 |
| Income and other taxes payable | 424,436 | 407,727 |
| Payroll and social charges | 337,805 | 288,065 |
| Lease liabilities | 1,425,518 | 1,412,398 |
| Deferred income taxes | 1,175,082 | 1,169,300 |
| Provisions for legal proceedings | 223,544 | 209,358 |
| Related party payables | 142,536 | 190,998 |
| Derivative liabilities | 101,901 | 114,376 |
| Other non-current liabilities | 50,086 | 42,180 |
| TOTAL NON-CURRENT LIABILITIES | 25,196,700 | 24,091,885 |
| EQUITY | 20 | |
| Share capital common shares | 41,560 | 35,114 |
| Reserves | 8,064,257 | 6,582,694 |
| Undistributed results | 118,485 | 2,085,772 |
| Attributable to company shareholders | 8,224,302 | 8,703,580 |
| Attributable to non-controlling interest | 834,759 | 819,211 |
| TOTAL EQUITY | 9,059,061 | 9,522,791 |
| TOTAL LIABILITIES AND EQUITY | 45,838,376 | 45,156,486 |
Statements of cash flow (Unaudited)
(in thousands)
| Description | Six-month period ended June 30, 2026 | Six-month period ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net income | 145,415 | 1,150,648 |
| Adjustments for: | ||
| Depreciation and amortization | 1,256,587 | 1,100,838 |
| Expected credit losses | 4,959 | 13,258 |
| Share of loss of equity-accounted investees | (14,794) | (10,556) |
| Gain on sales of assets | (13,261) | (8,880) |
| Tax expense | (58,806) | 279,954 |
| Net finance expense | 1,009,781 | 567,950 |
| Share-based compensation | 25,762 | 14,116 |
| Provisions for legal proceedings | 72,988 | 15,565 |
| Impairment of property, plant and equipment | 22,624 | 13,613 |
| Net realizable value inventory adjustments | 31,995 | 20,419 |
| DOJ (Department of Justice) and antitrust agreements | 157,375 | 133,638 |
| Fair value adjustment of biological assets | 71,538 | (86,487) |
| Provision for avian influenza | — | 5,612 |
| 2,712,163 | 3,209,688 | |
| Changes in assets and liabilities: | ||
| Trade accounts receivable | 683,555 | 160,085 |
| Inventories | (824,622) | (955,245) |
| Recoverable taxes | (19,460) | 93,786 |
| Other current and non-current assets | (88,222) | (362,166) |
| Biological assets | (415,776) | (398,066) |
| Trade accounts payable and supply chain finance | (437,706) | (575,413) |
| Taxes paid in installments | (23,039) | (51,896) |
| Other current and non-current liabilities | (294,141) | 179,416 |
| DOJ and Antitrust agreements payment/reimbursement | (98,767) | (261,212) |
| Income taxes paid | (400,299) | (550,897) |
| Changes in operating assets and liabilities | (1,918,477) | (2,721,608) |
| Cash from operating activities | 793,686 | 488,080 |
| Interest paid | (810,814) | (604,927) |
| Interest received | 79,886 | 73,699 |
| Net cash flows used in operating activities | 62,758 | (43,148) |
| Cash flow from investing activities | ||
| Purchases of property, plant and equipment | (1,178,902) | (714,122) |
| Dividends received | 229 | 4,124 |
| Purchase and disposals of intangible assets | (7,194) | (2,554) |
| Additions (disposals) to investments in joint ventures | 26,352 | (165,271) |
| Related party transactions | (16,750) | 4,650 |
| Proceeds from sale of property, plant and equipment | 48,109 | 35,615 |
| Cash used in investing activities | (1,128,156) | (837,558) |
| Cash flow from financing activities | ||
| Proceeds from loans and financings | 3,865,514 | 4,494,204 |
| Payments of loans and financings | (2,700,661) | (4,676,359) |
| Derivatives instruments received (settled) | (6,483) | (52,863) |
| Margin cash | (35,429) | (44,400) |
| Dividends paid | (1,039,099) | (1,573,855) |
| Dividends paid to non-controlling interest | (2,920) | (266,417) |
| Disposal of treasury shares | 1,234 | — |
| Payments of leasing contracts | (220,810) | (215,060) |
| Others | (2,768) | — |
| Cash used in financing activities | (141,422) | (2,334,750) |
| Effect of exchange rate changes on cash and cash equivalents | 110,804 | 120,535 |
| Net change in cash and cash equivalents | (1,096,016) | (3,094,921) |
| Cash and cash equivalents beginning of period | 4,565,136 | 5,613,672 |
| Cash and cash equivalents at the end of period | 3,469,120 | 2,518,751 |
Amounts as printed on the EDGAR/iXBRL face — (in thousands). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗